comparemela.com

Latest Breaking News On - Bernard prendergast - Page 2 : comparemela.com

More TRILUMINATE Patients Flesh Out Tricuspid TEER s Impact

The data further confirm the safety and efficacy of the device and add to better understanding of patient selection, researchers say.

United statesCity ofUnited kingdomNew yorkDavidh adamsBernard prendergastGorav ailawadiDavidj cohenRebecca hahnPhilipp lurzPinak shahPresbyterian columbia university irving medical centerMd university of michiganDrug administrationPhd heart center leipzigKansas city cardiomyopathy questionnaire

Tricuspid Regurgitation Device Passes in Pivotal Trial

JenaValve device hits benchmarks with improvement in pacemaker rates

United statesNew yorkNorthwestern universityClyde yancyBernard prendergastKendra grubbPinak shahDavid cohenCatheterization lab at brighamCardiovascular research foundationValve centerJenavalve trilogyCardiovascular therapeuticsCardiovascular researchEmory structural heartCleveland clinic london

Some Surprises in Low-Risk TAVI Follow-up: PARTNER 3 and Evolut Trials

TAVI benefits were attenuated and mortality trended higher in PARTNER 3 at 5 years. For Evolut, TAVI maintained an edge.

United statesNew yorkGilbert tangPinak shahDavid cohenMichael reardonEdwards lifesciencesKendra grubbBernard prendergastDrug administrationMd emory universityPresbyterian columbia university irving medical centerMd cardiovascular research foundation stMd methodist debakey heart vascular centerJournal of the american college cardiologyMount sinai health system

Low-Risk TAVR Converging or Diverging With Surgical Outcomes, Depending on the Valve

Intermediate-term reports from PARTNER 3 and Evolut Low Risk trials

United statesNew yorkColl cardiolNicole louBernard prendergastMichael reardonPinak shahKendra grubbJournal of the american college cardiologyEmory university in atlantaHouston methodist debakey heart vascular centerPresbyterian columbia university irving medical centerCardiovascular research foundationEvolut low riskMartin leonColumbia university irving medical center

Will Tricuspid Innovation Outpace Mitral? Some Hopes, Some Second-Guessing

Pivotal results for tricuspid repair and replacement trials are pending, but experts agree, today’s questions are just the start.

New yorkUnited statesCity ofUnited kingdomComunidad autonoma de catalunaAzeem latibGeorg nickenigNeil famJuan granadaFrancesco maisanoBernard prendergastAnita asgarMarta sitgesSan raffaele scientific instituteMd cardiovascular research foundationMd montreal heart institute

vimarsana © 2020. All Rights Reserved.